XRP Price Jumps Back After Wild Swing – Ripple’s Token Eyes ETF Catalyst in Volatile Crypto Market
9 November 2025
3 mins read

XRP Price Today (Nov 9, 2025): XRP Holds Near $2.26 as 21Shares’ XRP ETF Filing Dominates Headlines

Updated: Nov 9, 2025, 10:25 UTC


Key takeaways

  • Spot price: XRP is trading around $2.26 this morning, keeping market cap near $136B with ~$1.6B in 24‑hour volume.
  • Intraday range: Today’s session has ranged roughly $2.24–$2.30 so far.
  • Today’s big story:21Shares filed Amendment No. 3 to its S‑1 for a 21Shares XRP ETF on Nov 7, with analysts on X highlighting a “20‑day clock” toward potential effectiveness; the filing itself still carries standard Section 8(a) delaying language. SEC+1
  • Context: Ripple’s momentum this week includes a $500M round at a $40B valuation—a backdrop that keeps institutional interest elevated.

XRP price snapshot for Sunday, Nov 9, 2025

  • Live price:$2.2619
  • Market cap:$135.96B (ranked #4)
  • 24h volume:$1.63B
    Data: CoinDesk live pricing dashboard.
  • Today’s trading range:$2.2408 (low) – $2.2973 (high)
    Data: Investing.com intraday data for Nov 9, 2025.
  • 7‑day context: XRP remains lower on the week after last week’s selloff; CoinDesk’s dashboard shows XRP still down vs. 7‑day levels.

What moved XRP today

1) 21Shares advances its U.S. spot XRP ETF

21Shares filed Amendment No. 3 to its S‑1 on Nov 7, detailing the 21Shares XRP ETF (expected listing on Cboe BZX under ticker “TOXR”). The prospectus is dated Nov 7, 2025 and—importantly—contains the customary preface that effectiveness will occur in accordance with Section 8(a) (i.e., it still includes standard delaying language). SEC

Separately, Bloomberg ETF analyst Eric Balchunas flagged that 21Shares “dropped an 8(a),” which ETF watchers often treat as a late‑stage step toward launch. Coverage across crypto media framed this as starting a “20‑day” window toward potential effectiveness, though the practical timing still depends on the SEC and the exact text of the filings. Bottom line: momentum is real, but a hard launch date is not guaranteed from today’s paperwork alone. X (formerly Twitter)+1

Some outlets reported a quick price pop toward $2.32 after the ETF progress headlines—typical “headline beta” for XRP. AMBCrypto

2) Institutional backdrop: Ripple’s $500M raise at $40B

Through the week, Ripple confirmed a $500 million strategic funding round at a $40B valuation (led by Fortress Investment Group and Citadel Securities), reinforcing institutional interest around Ripple’s product stack (payments, custody, and stablecoin RLUSD). This is background, but it colors sentiment and flows into weekend trading.

3) Post‑Swell digestion and positioning

Following Ripple Swell 2025 (Nov 4–5), traders largely “bought the rumor, sold the news,” with XRP giving back part of last week’s rally—another factor behind today’s cautious tone. TipRanks


Levels to watch

  • Immediate support:$2.21–$2.24 (this week’s lower band and today’s session low cluster).
  • Near‑term resistance:$2.40–$2.53 (recent supply zone and last week’s local highs).

Traders are treating $2.20–$2.25 as a battleground: lose it convincingly and momentum screens risk a retest of the early‑November lows; reclaim and hold $2.40+ and models start flipping back to “ETF‑anticipation” mode.


What’s next on the calendar

  • ETF paperwork watch: Keep an eye on the 21Shares XRP ETF page on SEC EDGAR for any further amendments (e.g., removal of delaying language) and potential Form 8‑A submissions tied to listing mechanics. The Nov 7 S‑1/A confirms progress; whether a 20‑day path is truly “in effect” hinges on subsequent filings and SEC posture. SEC
  • Macro and crypto beta: XRP remains sensitive to broad crypto risk sentiment led by BTC; rebounds or risk‑off in majors can bleed into XRP intraday. (Market context: majors steadied late week.)

Background: where the legal cloud stands

For context, the SEC v. Ripple saga concluded earlier this year with a court‑approved penalty and clarity that exchange‑traded XRP sales are not securities—a prerequisite for serious ETF traction in the U.S. This legal backdrop is a key reason the ETF conversation exists at all.


Editor’s note on sources & methodology

  • Prices/market stats are drawn from CoinDesk (live dashboard) and Investing.com (intraday table for today). Figures can vary by venue and update cadence.
  • ETF status is sourced from the SEC’s S‑1/A (Nov 7, 2025) for the 21Shares XRP ETF and contemporaneous analyst commentary on X plus industry coverage; we distinguish between on‑chain filings and third‑party interpretations.
  • Corporate/investor context comes from Reuters and the Financial Times.

Disclaimer

This article is for news and information purposes only and does not constitute investment advice. Digital assets are volatile and carry risk. Always do your own research.

Stock Market Today

  • Shell in Exclusive Talks to Sell Sprng Energy as Investors Eye Core Oil Focus
    May 14, 2026, 3:32 PM EDT. Shell is in exclusive negotiations to sell Sprng Energy, its 5GW Indian renewable platform, with Aditya Birla Group and KKR as leading bidders. This move reflects mounting shareholder pressure to prioritize core oil and gas operations. Shell's shares trade at £31.49, up 14.1% year-to-date but 6.7% down over the past 30 days, currently about 15% below analyst targets. The sale could alter Shell's earnings mix and risk profile by reducing renewables exposure. Investors are closely watching the sale price, potential gains or losses, and the use of proceeds, including options like share buybacks or debt reduction. Dividend stability remains a concern amid portfolio adjustments. Upcoming deal details will clarify Shell's strategy on capital allocation and the role of renewables in emerging markets.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

14 May 2026
Smart Powerr shares jumped to 78.83 cents, up nearly 59 cents from the previous close, after hitting 90.37 cents intraday. The surge followed news that Nasdaq warned the company over its sub-$1 share price and possible suspension. Trading volume reached about 395 million shares. The company said a hearing request would delay any suspension but gave no assurance of keeping its Nasdaq listing.
Opendoor (OPEN) prices 180.6M-share sale at $6.56, details warrant dividend after Q3 loss — What it means for investors (Nov. 8, 2025)
Previous Story

Opendoor (OPEN) prices 180.6M-share sale at $6.56, details warrant dividend after Q3 loss — What it means for investors (Nov. 8, 2025)

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
Next Story

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Go toTop